Second-trimester prenatal screening markers for Down syndrome in women with insulin-dependent diabetes mellitus

被引:33
作者
Huttly, W [1 ]
Rudnicka, A [1 ]
Wald, NJ [1 ]
机构
[1] Barts & London Queen Marys Sch Med & Dent, Wolfson Inst Prevent Med, London EC1M 6BQ, England
关键词
maternal serum screening; IDDM second-trimester marker levels;
D O I
10.1002/pd.994
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Published studies have shown that some serum markers used in screening for Down syndrome tend to be lower among women with insulin-dependent diabetes mellitus (IDDM). On this basis, many screening programmes adjust the marker levels to take account of this difference. Recent studies suggested that the marker levels were not different, and so adjustment may no longer be needed, possibly because of better diabetic control. Data from a prenatal screening programme for Down syndrome were examined to see whether the median values of second-trimester screening markers were still reduced in pregnant women with IDDM. A total of 366 women with IDDM singleton pregnancies without Down syndrome were identified from the screening programme at Barts from 1989 to 2002. After allowing for maternal weight, the median multiples of the median (MoM) for IDDM-unaffected singleton pregnancies were as follows: 0.88 (95% confidence interval 0.84-0.93) for alphafetoprotein (AFP), 0.95 (0.91-0.99) for unconjugated oestriol (uE(3)), 0.90 (0.80-1.01) for total human chorionic gonadotrophin (total hCG), 0.98 (0.88-1.08) for free beta-hCG, and 0.99 (0.89-1.10) for inhibin-A. The median levels for AFP and uE(3) were statistically significantly lower in pregnant women with IDDM. The other markers were not significantly different in women with and without IDDM. There remains a case for adjusting AFP and uE(3) levels in women with IDDM in prenatal screening programmes for Down syndrome. Copyright (C) 2004 John Wiley Sons, Ltd.
引用
收藏
页码:804 / 807
页数:4
相关论文
共 21 条
[1]  
Canick JA, 1990, AM J HUM GENET, V47, pA270
[2]  
Crossley JA, 1996, PRENATAL DIAG, V16, P1039, DOI 10.1002/(SICI)1097-0223(199611)16:11<1039::AID-PD985>3.0.CO
[3]  
2-#
[4]   Correction for insulin-dependent diabetes in maternal serum α-fetoprotein testing has outlived its usefulness [J].
Evans, MI ;
Harrison, HH ;
O'Brien, JE ;
Dvorin, E ;
Huang, XH ;
Krivchenia, EL ;
Reece, EA .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2002, 187 (04) :1084-1086
[5]  
GREENE MF, 1988, LANCET, V2, P345
[6]  
HENRIQUES CU, 1993, OBSTET GYNECOL, V82, P960
[7]   Epidemiological evidence that maternal diabetes does not appear to increase the risk for Down syndrome [J].
Martínez-Frías, ML ;
Rodríguez-Pinilla, E ;
Bermejo, E ;
Prieto, L .
AMERICAN JOURNAL OF MEDICAL GENETICS, 2002, 112 (04) :335-337
[8]   HUMAN CHORIONIC-GONADOTROPIN AND UNCONJUGATED ESTRIOL MEASUREMENTS IN INSULIN-DEPENDENT DIABETIC PREGNANT-WOMEN BEING SCREENED FOR FETAL DOWN-SYNDROME [J].
PALOMAKI, GE ;
KNIGHT, GJ ;
HADDOW, JE .
PRENATAL DIAGNOSIS, 1994, 14 (01) :65-68
[9]   Strict glycemic control in diabetic pregnancy - implications for second-trimester screening for Down syndrome [J].
Peled, Y ;
Gilboa, Y ;
Perri, T ;
Shohat, M ;
Chen, R ;
Bar, J ;
Hod, M ;
Pardo, J .
PRENATAL DIAGNOSIS, 2003, 23 (11) :888-890
[10]  
REECE EA, 1987, LANCET, V2, P275